Josias Pontes - 14 Jun 2021 Form 3 Insider Report for Sigilon Therapeutics, Inc.

Role: VP, Head of Finance
Signature: /s/ Matthew Kowalsky, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 14 Jun 2021
Net transactions value: $0
Form type: 3
Filing time: 21 Jun 2021, 16:20:45 UTC
Next filing: 04 Oct 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	SGTX	Common Stock						600	14 Jun 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	SGTX	Stock Option (Right to Buy)							14 Jun 2021	Common Stock	66,666	$8.87	Direct	F1
holding	SGTX	Stock Option (Right to Buy)							14 Jun 2021	Common Stock	888	$9.39	Direct	F2
holding	SGTX	Stock Option (Right to Buy)							14 Jun 2021	Common Stock	25,000	$39.81	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option vested as to 25% of the underlying shares of common stock on December 5, 2020, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.
F2	The option vested as to 50% of the underlying shares of common stock on October 23, 2020, based on the Company's satisfaction of certain performance criteria. The option shall vest as to 50% of the underlying shares of common stock on October 23, 2021, the first anniversary of the vesting commencement date.
F3	The option vests as to 25% of the underlying shares of common stock on February 11, 2022, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.